Recombinant human thyrotropin in the management of thyroid disorders

Expert Opinion on Biological Therapy

Volumn 8, Issue 11, 2008, Pages 1721-1732

  Paz Filho, Gilberto J ^a,b   Graf, Hans ^a,b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (United States)

Author keywords

Goiter; Radioiodine; Recombinant TSH; Thyroid cancer; Thyrotropin

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; IODINE 131; LEVOTHYROXINE; PLACEBO; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE; THYROTROPIN;

ADJUVANT THERAPY; ASTHENIA; CLINICAL TRIAL; CONGENITAL HYPOTHYROIDISM; DIARRHEA; DIFFERENTIATED THYROID CARCINOMA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; FATIGUE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INSOMNIA; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA; NODULAR GOITER; PARESTHESIA; REVIEW; SINGLE DRUG DOSE; THYROID CARCINOMA; THYROID DISEASE; THYROIDECTOMY; THYROIDITIS; THYROTROPIN BLOOD LEVEL; TUMOR BLEEDING; VOMITING;

AMIODARONE; CLINICAL TRIALS AS TOPIC; GOITER; HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; THYROID DISEASES; THYROID HORMONES; THYROID NEOPLASMS; THYROTOXICOSIS; THYROTROPIN; TREATMENT OUTCOME;

EID: 56249146704     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.11.1721     Document Type: Review

References (71)

1. Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (NY) 1993;11:1014-24
2. Grossmann M, Weintraub BD, Szkudlinski MW. Novel insights into the molecular mechanisms of human thyrotropin action: structural, physiological, and therapeutic implications for the glycoprotein hormone family. Endocr Rev 1997;18:476-501
3. Szkudlinski MW, Thotakura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993;133:1490-503
4. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-51
5. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31
6. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004;351:1764-71
7. American Cancer Society. Cancer Facts & Figures 2008. Atlanta: American Cancer Society; 2008
8. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42
9. Maia AL, Ward LS, Carvalho GA, et al. [Thyroid nodules and differentiated thyroid cancer: Brazilian consensus]. Arq Bras Endocrinol Metabol 2007;51:867-93
10. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803
11. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76
12. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9
13. Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005;15:1147-55
14. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865-9
15. Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52
16. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8
17. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-5
18. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 2006;27:627-32
19. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32
20. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54
21. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6
22. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84
23. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-70
24. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74
25. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:76-81
26. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47
27. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5
28. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7
29. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7
30. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73
31. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85
32. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41
33. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12
34. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-86
35. Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:5-11
36. Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:1121-30
37. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49-64
38. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999;84:3636-41
39. Wesche MF, Tiel-v-Buul MM, Smits NJ, et al. Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. Eur J Endocrinol 1995;132:86-7
40. Hermus AR, Huysmans DA. Treatment of benign nodular thyroid disease. N Engl J Med 1998;338:1438-47
41. Hegedus L, Hansen BM, Knudsen N, et al. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ 1988;297:661-2
42. Nygaard B, Faber J, Hegedus L, et al. 131I treatment of nodular non-toxic goitre. Eur J Endocrinol 1996;134:15-20
43. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000;85:3592-6
44. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001;86:5330-6
45. Diehl LA, Romaldini JH, Graf H, et al. Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey. Clin Endocrinol (Oxf) 2006;65:433-8
46. Lawrence JE, Emerson CH, Sullaway SL, et al. The effect of recombinant human TSH on the thyroid (123)I uptake in iodide treated normal subjects. J Clin Endocrinol Metab 2001;86:437-40
47. Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003;88:3121-9
48. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract 2003;9:204-9
49. Duick DS, Baskin HJ. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter. Endocr Pract 2004;10:253-60
50. Cohen O, Ilany J, Hoffman C, et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 2006;154:243-52
51. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005;90:2775-80
52. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 2007;40:1661-70
53. Paz-Filho G, Mesa C, Carvalho G, et al. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after two years. Clin Endocrinol (Oxf) 2007;69:345-6
54. Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004;60:300-8
55. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006;166:1476-82
56. Bonnema SJ, Nielsen VE, Boel-Jorgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007;92:3424-8
57. Medeiros-Neto G, Marui S, Knobel M. An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 2008;33:109-17
58. Fugazzola L, Persani L, Mannavola D, et al. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol (Oxf) 2003;59:230-6
59. Tiosano D, Even L, Shen Orr Z, et al. Recombinant thyrotropin in the diagnosis of congenital hypothyroidism. J Clin Endocrinol Metab 2007;92:1434-7
60. Filipsson H, Nystrom E, Johannsson G. Exploring the use of recombinant human thyrotropin in the diagnosis of central hypothyroidism. Eur J Endocrinol 2008;159:153-60
61. Albino C, Paz-Filho G, Graf H. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis. Clin Endocrinol 2008 [Epub ahead of print]
62. Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156:531-8
63. Mernagh P, Campbell S, Dietlein M, et al Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155:405-14
64. Barbaro D, Boni G. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Eur J Surg Oncol 2007;33:535-40
65. Potzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 2006;65:519-23
66. Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 2008;18:509-16
67. Norden MM, Larsson F, Tedelind S, et al. Down-regulation of the sodium/ iodide symporter explains 131I-induced thyroid stunning. Cancer Res 2007;67:7512-7
68. Silberstein EB. Comparison of outcomes after 123;I versus 131;I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007;48:1043-6
69. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7
70. Zophel K, Wunderlich G, Kotzerke J. A highly sensitive thyroglobulin assay has superior diagnostic sensitivity for recurrence of differentiated thyroid cancer in patients undergoing TSH suppression. J Nucl Med 2006;47:552-3; author reply 3
71. Barca MF, Gruppi C, Oliveira MT, et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine 2007;32:175-81